Description
The antibodies in this kit have been generated against and affinity purified using a lysate of BL21(DE3) strain and characterized by Antibody Affinity Extraction and Mass Spectrometry demonstrating reactivity to the majority of HCPs. This new Cygnus Technologies' BL21(DE3) HCP ELISA Kit provides the specificity and sensitivity (LOD ~0.4 ng/ml, LLOQ ~3 ng/ml) to detect HCPs with reproducibility that supports regulatory compliance, aiding in optimal purification process development, process control, routine quality control, and product release testing.